155 related articles for article (PubMed ID: 37594129)
1. USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination‑mediated degradation.
Lv T; Zhang B; Jiang C; Zeng Q; Yang J; Zhou Y
Int J Oncol; 2023 Oct; 63(4):. PubMed ID: 37594129
[TBL] [Abstract][Full Text] [Related]
2. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
3. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
[TBL] [Abstract][Full Text] [Related]
4. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
[TBL] [Abstract][Full Text] [Related]
5. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
6. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
[TBL] [Abstract][Full Text] [Related]
7. Oviductus ranae protein hydrolysate (ORPH) inhibits the growth, metastasis and glycolysis of HCC by targeting miR-491-5p/PKM2 axis.
Xu Q; Dou C; Liu X; Yang L; Ni C; Wang J; Guo Y; Yang W; Tong X; Huang D
Biomed Pharmacother; 2018 Nov; 107():1692-1704. PubMed ID: 30257387
[TBL] [Abstract][Full Text] [Related]
8. PKM2 promotes cell metastasis and inhibits autophagy via the JAK/STAT3 pathway in hepatocellular carcinoma.
Yu Z; Wang D; Tang Y
Mol Cell Biochem; 2021 May; 476(5):2001-2010. PubMed ID: 33512635
[TBL] [Abstract][Full Text] [Related]
9. USP35 promotes HCC development by stabilizing ABHD17C and activating the PI3K/AKT signaling pathway.
Wang L; Wang J; Ma X; Ju G; Shi C; Wang W; Wu J
Cell Death Discov; 2023 Nov; 9(1):421. PubMed ID: 37993419
[TBL] [Abstract][Full Text] [Related]
10. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture.
Dong T; Yan Y; Chai H; Chen S; Xiong X; Sun D; Yu Y; Deng L; Cheng F
Biomed Pharmacother; 2015 Feb; 69():277-84. PubMed ID: 25661370
[TBL] [Abstract][Full Text] [Related]
11. LncRNA HClnc1 facilitates hepatocellular carcinoma progression by regulating PKM2 signaling and indicates poor survival outcome after hepatectomy.
Zhu Q; Lei Z; Xu C; Zhang Z; Yu Z; Cheng Z; Xiao P; Li S; Yu W; Zhou J
Cancer Med; 2023 Jul; 12(13):14526-14544. PubMed ID: 37212467
[TBL] [Abstract][Full Text] [Related]
12. PKM2 Drives Hepatocellular Carcinoma Progression by Inducing Immunosuppressive Microenvironment.
Li TE; Wang S; Shen XT; Zhang Z; Chen M; Wang H; Zhu Y; Xu D; Hu BY; Wei R; Zheng Y; Dong QZ; Qin LX
Front Immunol; 2020; 11():589997. PubMed ID: 33193421
[TBL] [Abstract][Full Text] [Related]
13. ARHGAP24 represses β-catenin transactivation-induced invasiveness in hepatocellular carcinoma mainly by acting as a GTPase-independent scaffold.
Yang W; Wang B; Yu Q; Liu T; Li T; Tian T; Jin A; Ding L; Chen W; Wang H; Xian J; Pan B; Zhou J; Fan J; Yang X; Guo W
Theranostics; 2022; 12(14):6189-6206. PubMed ID: 36168627
[No Abstract] [Full Text] [Related]
14. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
[TBL] [Abstract][Full Text] [Related]
15. GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism.
Zhou Q; Yin Y; Yu M; Gao D; Sun J; Yang Z; Weng J; Chen W; Atyah M; Shen Y; Ye Q; Li CW; Hung MC; Dong Q; Zhou C; Ren N
Redox Biol; 2022 Oct; 56():102458. PubMed ID: 36116159
[TBL] [Abstract][Full Text] [Related]
16. PKM2 regulates hepatocellular carcinoma cell epithelial-mesenchymal transition and migration upon EGFR activation.
Fan FT; Shen CS; Tao L; Tian C; Liu ZG; Zhu ZJ; Liu YP; Pei CS; Wu HY; Zhang L; Wang AY; Zheng SZ; Huang SL; Lu Y
Asian Pac J Cancer Prev; 2014; 15(5):1961-70. PubMed ID: 24716919
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1.
Qiu Y; Huang D; Sheng Y; Huang J; Li N; Zhang S; Hong Z; Yin X; Yan J
Exp Cell Res; 2021 Aug; 405(1):112646. PubMed ID: 34029571
[TBL] [Abstract][Full Text] [Related]
18. Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p/PKM2 Axis Under Hypoxic Stress.
Li Q; Pan X; Zhu D; Deng Z; Jiang R; Wang X
Hepatology; 2019 Oct; 70(4):1298-1316. PubMed ID: 31004447
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Zhao R; Li L; Yang J; Niu Q; Wang H; Qin X; Zhu N; Shi A
Pathol Oncol Res; 2020 Apr; 26(2):853-860. PubMed ID: 30852741
[TBL] [Abstract][Full Text] [Related]
20. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
